414 research outputs found
Inhibitory control in mind and brain 2.0: blocked-input models of saccadic countermanding.
The interactive race model of saccadic countermanding assumes that response inhibition results from an interaction between a go unit, identified with gaze-shifting neurons, and a stop unit, identified with gaze-holding neurons, in which activation of the stop unit inhibits the growth of activation in the go unit to prevent it from reaching threshold. The interactive race model accounts for behavioral data and predicts physiological data in monkeys performing the stop-signal task. We propose an alternative model that assumes that response inhibition results from blocking the input to the go unit. We show that the blocked-input model accounts for behavioral data as accurately as the original interactive race model and predicts aspects of the physiological data more accurately. We extend the models to address the steady-state fixation period before the go stimulus is presented and find that the blocked-input model fits better than the interactive race model. We consider a model in which fixation activity is boosted when a stop signal occurs and find that it fits as well as the blocked input model but predicts very high steady-state fixation activity after the response is inhibited. We discuss the alternative linking propositions that connect computational models to neural mechanisms, the lessons to be learned from model mimicry, and generalization from countermanding saccades to countermanding other kinds of responses
Анализ влияния направления ствола горизонтальных скважин на продуктивность на примере Х месторождения Западной Сибири
A Systemically-Administered Small Molecule Antagonist of CCR9 Acts as a Tissue-Selective Inhibitor of Lymphocyte Trafficking
A goal for developers of immunomodulatory drugs has long been a systemically administered small molecule that can selectively inhibit inflammation in specific tissues. The chemokine receptor CCR9 is an attractive target for this approach, as entry of T cells into the small intestine from blood requires interaction between CCR9 and its ligand CCL25. We have tested the ability of a small molecule CCR9 antagonist, CCX8037, to inhibit antigen-mediated T cell accumulation in the intestine. This compound prevented accumulation of gut-imprinted antigen-specific CD8 T cells within epithelium of the small intestine. Interestingly, the antagonist did not affect the robust generation of gut-imprinted CD8 T cells within mesenteric lymph nodes. To distinguish “gut-selective” from “general” T cell inhibition, we tested the drug’s ability to influence accumulation of T cells within skin, a tissue in which CCR9 plays no known role, and we found no appreciable effect. This study demonstrates the feasibility of creating systemically-administered pharmaceuticals capable of tissue-selective immune modulation. This proof of concept is of utmost importance for designing effective treatments against various autoimmune disorders localized to a specific tissue
The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells
<p>Abstract</p> <p>Background</p> <p>Migration of metastatic tumor cells from the bloodstream into lymph nodes is thought to be facilitated by expression of the chemokine receptors CCR7, CXCR4 and, for B cell-derived tumors, CXCR5. Expression of their respective chemokine ligands (CCL19, CCL21, CXCL12 and CXCL13) by endothelial cells inside the lymph nodes facilitates the trans-endothelial migration (TEM) of these cells through high endothelial venules into the lymph node parenchyma. It is known that CXCR7, a second CXCL12 receptor, regulates TEM of CXCR4+CXCR7+ tumor cells towards a CXCL12 source. In this study, we set out to assess the potential stimulation by CXCL12 of tumor cell TEM towards other chemokines and whether CXCR7 might be able to regulate such effects.</p> <p>Methods</p> <p>The human Burkitt's lymphoma cell line NC-37, which expresses CXCR4, CXCR5, CXCR7 and CCR7, was selected as a model system. TEM of these cells through a human HUVEC endothelial cell monolayer was used as the main model system for these studies. Regulation of their TEM behavior by various concentrations of the various cognate chemokines for the above-mentioned receptors, placed in either the source or target wells of modified Boyden chamber migration plates, was assessed by quantifying the number of cells migrated under each experimental condition.</p> <p>Results</p> <p>Exposure of CXCR4<sup>+</sup>CXCR7<sup>+ </sup>cancer cells to CXCL12 greatly potentiated their TEM towards the chemokines CCL19 and CXCL13. This CXCL12-potentiated TEM was inhibited by the second CXCR7 chemokine ligand, CXCL11, as well as CXCR7-specific small molecule antagonists and antibodies. In contrast, the CXCR4 antagonist AMD3100 was less effective at inhibiting CXCL12-potentiated TEM. Thus, CXCR7 antagonists may be effective therapeutic agents for blocking CXCL12-mediated migration of CXCR4<sup>+</sup>CXCR7<sup>+ </sup>tumor cells into lymph nodes, regardless of whether the cancer cells follow a CXCL12 gradient or whether serum CXCL12 stimulates their migration towards CCR7 and CXCR5 chemokines in the lymph nodes.</p
RANTES Secretion by Gene-Modified Tumor Cells Results in Loss of Tumorigenicity In Vivo: Role of Immune Cell Subpopulations
Overview summary Members of the chemokine superfamily mediate potent and selective chemoattraction of a variety of immune cell subsets, which is concentration dependent. This important and novel biologic activity raises the possibility of using chemokines as adjuvants in cancer vaccine strategies. We describe here the in vitro chemotactic capacity of RANTES for murine CD8+ tumor-infiltrating lymphocytes (TIL). Moreover, murine fibrosarcoma cells transfected with the cDNA encoding RANTES and secreting high levels of this chemokine become nontumorigenic in immunocompetent mice. The antitumor effect of RANTES is dependent on inherent tumor immunogenicity and is mediated through the participation of host-derived T cells and macrophages. Thus, the general chemoattractant properties exhibited by RANTES in vitro appear to be relevant in an in vivo model. These data warrant further investigation of other distinct members of the chemokine superfamily for their potential use, either alone or in combination, in gene therapy approaches that employ tumor cells as immunogens.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/63285/1/hum.1996.7.13-1545.pd
CCR6, a CC Chemokine Receptor that Interacts with Macrophage Inflammatory Protein 3α and Is Highly Expressed in Human Dendritic Cells
Dendritic cells initiate immune responses by ferrying antigen from the tissues to the lymphoid organs for presentation to lymphocytes. Little is known about the molecular mechanisms underlying this migratory behavior. We have identified a chemokine receptor which appears to be selectively expressed in human dendritic cells derived from CD34+ cord blood precursors, but not in dendritic cells derived from peripheral blood monocytes. When stably expressed as a recombinant protein in a variety of host cell backgrounds, the receptor shows a strong interaction with only one chemokine among 25 tested: the recently reported CC chemokine macrophage inflammatory protein 3α. Thus, we have designated this receptor as the CC chemokine receptor 6. The cloning and characterization of a dendritic cell CC chemokine receptor suggests a role for chemokines in the control of the migration of dendritic cells and the regulation of dendritic cell function in immunity and infection
Recommended from our members
Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias
Both CXC chemokine receptor 4 (CXCR4) and atypical chemokine receptor 3 (ACKR3) are activated by the chemokine CXCL12 yet evoke distinct cellular responses. CXCR4 is a canonical G protein–coupled receptor (GPCR), whereas ACKR3 is intrinsically biased for arrestin. The molecular basis for this difference is not understood. Here, we describe cryo-EM structures of ACKR3 in complex with CXCL12, a more potent CXCL12 variant, and a small-molecule agonist. The bound chemokines adopt an unexpected pose relative to those established for CXCR4 and observed in other receptor-chemokine complexes. Along with functional studies, these structures provide insight into the ligand-binding promiscuity of ACKR3, why it fails to couple to G proteins, and its bias toward β-arrestin. The results lay the groundwork for understanding the physiological interplay of ACKR3 with other GPCRs
Adaptive Sampling of Information in Perceptual Decision-Making
In many perceptual and cognitive decision-making problems, humans sample multiple noisy information sources serially, and integrate the sampled information to make an overall decision. We derive the optimal decision procedure for two-alternative choice tasks in which the different options are sampled one at a time, sources vary in the quality of the information they provide, and the available time is fixed. To maximize accuracy, the optimal observer allocates time to sampling different information sources in proportion to their noise levels. We tested human observers in a corresponding perceptual decision-making task. Observers compared the direction of two random dot motion patterns that were triggered only when fixated. Observers allocated more time to the noisier pattern, in a manner that correlated with their sensory uncertainty about the direction of the patterns. There were several differences between the optimal observer predictions and human behaviour. These differences point to a number of other factors, beyond the quality of the currently available sources of information, that influences the sampling strategy
Recommended from our members
Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?
This work was supported by National Institute of Biomedical Imaging and Bioengineering Grant No. U54EB020403 (to the ENIGMA consortium)
- …